Abstract
Summary
The global market for Specialty Generics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Specialty Generics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Specialty Generics by region & country, by Type, and by Application.
The Specialty Generics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Specialty Generics.
Market Segmentation
By Company
Teva Pharmaceuticals Industries
Akorn, Inc.
Mylan N.V.
Mallinckrodt
Sandoz International GmbH
Pfizer, Inc.
Sun Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals
Apotex Corp.
Endo International plc.
Segment by Type:
Injectables
Oral
Others
Segment by Application
Retail Pharmacies
Specialty Pharmacies
Hospital Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Specialty Generics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Specialty Generics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Specialty Generics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Specialty Generics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Specialty Generics by region & country, by Type, and by Application.
The Specialty Generics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Specialty Generics.
Market Segmentation
By Company
Teva Pharmaceuticals Industries
Akorn, Inc.
Mylan N.V.
Mallinckrodt
Sandoz International GmbH
Pfizer, Inc.
Sun Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals
Apotex Corp.
Endo International plc.
Segment by Type:
Injectables
Oral
Others
Segment by Application
Retail Pharmacies
Specialty Pharmacies
Hospital Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Specialty Generics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Specialty Generics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Specialty Generics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Specialty Generics Product Introduction
1.2 Global Specialty Generics Market Size Forecast
1.3 Specialty Generics Market Trends & Drivers
1.3.1 Specialty Generics Industry Trends
1.3.2 Specialty Generics Market Drivers & Opportunity
1.3.3 Specialty Generics Market Challenges
1.3.4 Specialty Generics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Specialty Generics Players Revenue Ranking (2023)
2.2 Global Specialty Generics Revenue by Company (2019-2024)
2.3 Key Companies Specialty Generics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Specialty Generics Product Offered
2.5 Key Companies Time to Begin Mass Production of Specialty Generics
2.6 Specialty Generics Market Competitive Analysis
2.6.1 Specialty Generics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Specialty Generics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Specialty Generics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Injectables
3.1.2 Oral
3.1.3 Others
3.2 Global Specialty Generics Sales Value by Type
3.2.1 Global Specialty Generics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Specialty Generics Sales Value, by Type (2019-2030)
3.2.3 Global Specialty Generics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Retail Pharmacies
4.1.2 Specialty Pharmacies
4.1.3 Hospital Pharmacies
4.2 Global Specialty Generics Sales Value by Application
4.2.1 Global Specialty Generics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Specialty Generics Sales Value, by Application (2019-2030)
4.2.3 Global Specialty Generics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Specialty Generics Sales Value by Region
5.1.1 Global Specialty Generics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Specialty Generics Sales Value by Region (2019-2024)
5.1.3 Global Specialty Generics Sales Value by Region (2025-2030)
5.1.4 Global Specialty Generics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Specialty Generics Sales Value, 2019-2030
5.2.2 North America Specialty Generics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Specialty Generics Sales Value, 2019-2030
5.3.2 Europe Specialty Generics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Specialty Generics Sales Value, 2019-2030
5.4.2 Asia Pacific Specialty Generics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Specialty Generics Sales Value, 2019-2030
5.5.2 South America Specialty Generics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Specialty Generics Sales Value, 2019-2030
5.6.2 Middle East & Africa Specialty Generics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Specialty Generics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Specialty Generics Sales Value
6.3 United States
6.3.1 United States Specialty Generics Sales Value, 2019-2030
6.3.2 United States Specialty Generics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Specialty Generics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Specialty Generics Sales Value, 2019-2030
6.4.2 Europe Specialty Generics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Specialty Generics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Specialty Generics Sales Value, 2019-2030
6.5.2 China Specialty Generics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Specialty Generics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Specialty Generics Sales Value, 2019-2030
6.6.2 Japan Specialty Generics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Specialty Generics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Specialty Generics Sales Value, 2019-2030
6.7.2 South Korea Specialty Generics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Specialty Generics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Specialty Generics Sales Value, 2019-2030
6.8.2 Southeast Asia Specialty Generics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Specialty Generics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Specialty Generics Sales Value, 2019-2030
6.9.2 India Specialty Generics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Specialty Generics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Teva Pharmaceuticals Industries
7.1.1 Teva Pharmaceuticals Industries Profile
7.1.2 Teva Pharmaceuticals Industries Main Business
7.1.3 Teva Pharmaceuticals Industries Specialty Generics Products, Services and Solutions
7.1.4 Teva Pharmaceuticals Industries Specialty Generics Revenue (US$ Million) & (2019-2024)
7.1.5 Teva Pharmaceuticals Industries Recent Developments
7.2 Akorn, Inc.
7.2.1 Akorn, Inc. Profile
7.2.2 Akorn, Inc. Main Business
7.2.3 Akorn, Inc. Specialty Generics Products, Services and Solutions
7.2.4 Akorn, Inc. Specialty Generics Revenue (US$ Million) & (2019-2024)
7.2.5 Akorn, Inc. Recent Developments
7.3 Mylan N.V.
7.3.1 Mylan N.V. Profile
7.3.2 Mylan N.V. Main Business
7.3.3 Mylan N.V. Specialty Generics Products, Services and Solutions
7.3.4 Mylan N.V. Specialty Generics Revenue (US$ Million) & (2019-2024)
7.3.5 Mallinckrodt Recent Developments
7.4 Mallinckrodt
7.4.1 Mallinckrodt Profile
7.4.2 Mallinckrodt Main Business
7.4.3 Mallinckrodt Specialty Generics Products, Services and Solutions
7.4.4 Mallinckrodt Specialty Generics Revenue (US$ Million) & (2019-2024)
7.4.5 Mallinckrodt Recent Developments
7.5 Sandoz International GmbH
7.5.1 Sandoz International GmbH Profile
7.5.2 Sandoz International GmbH Main Business
7.5.3 Sandoz International GmbH Specialty Generics Products, Services and Solutions
7.5.4 Sandoz International GmbH Specialty Generics Revenue (US$ Million) & (2019-2024)
7.5.5 Sandoz International GmbH Recent Developments
7.6 Pfizer, Inc.
7.6.1 Pfizer, Inc. Profile
7.6.2 Pfizer, Inc. Main Business
7.6.3 Pfizer, Inc. Specialty Generics Products, Services and Solutions
7.6.4 Pfizer, Inc. Specialty Generics Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer, Inc. Recent Developments
7.7 Sun Pharmaceutical Industries Ltd.
7.7.1 Sun Pharmaceutical Industries Ltd. Profile
7.7.2 Sun Pharmaceutical Industries Ltd. Main Business
7.7.3 Sun Pharmaceutical Industries Ltd. Specialty Generics Products, Services and Solutions
7.7.4 Sun Pharmaceutical Industries Ltd. Specialty Generics Revenue (US$ Million) & (2019-2024)
7.7.5 Sun Pharmaceutical Industries Ltd. Recent Developments
7.8 Valeant Pharmaceuticals
7.8.1 Valeant Pharmaceuticals Profile
7.8.2 Valeant Pharmaceuticals Main Business
7.8.3 Valeant Pharmaceuticals Specialty Generics Products, Services and Solutions
7.8.4 Valeant Pharmaceuticals Specialty Generics Revenue (US$ Million) & (2019-2024)
7.8.5 Valeant Pharmaceuticals Recent Developments
7.9 Apotex Corp.
7.9.1 Apotex Corp. Profile
7.9.2 Apotex Corp. Main Business
7.9.3 Apotex Corp. Specialty Generics Products, Services and Solutions
7.9.4 Apotex Corp. Specialty Generics Revenue (US$ Million) & (2019-2024)
7.9.5 Apotex Corp. Recent Developments
7.10 Endo International plc.
7.10.1 Endo International plc. Profile
7.10.2 Endo International plc. Main Business
7.10.3 Endo International plc. Specialty Generics Products, Services and Solutions
7.10.4 Endo International plc. Specialty Generics Revenue (US$ Million) & (2019-2024)
7.10.5 Endo International plc. Recent Developments
8 Industry Chain Analysis
8.1 Specialty Generics Industrial Chain
8.2 Specialty Generics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Specialty Generics Sales Model
8.5.2 Sales Channel
8.5.3 Specialty Generics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer